MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fped.2026.1832504

Медицинская библиотека · Frontiers in pediatrics · 2026

Erxiekang emplastra as adjunctive therapy for acute gastroenteritis in children: a single-center retrospective cohort study.

Fang Cuiyun, Zhou Yuan, Jiang Zhongli, Su Xiaoxue, Fan Wei

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Standard treatments for pediatric acute gastroenteritis (AGE) have critical limitations in symptom control and medication adherence among young children. This study evaluated the efficacy and safety of Erxiekang Emplastra as adjunctive therapy for AGE in children aged 1 to 14 years.

METHODS

This single-center retrospective cohort study reviewed electronic medical records of children hospitalized with AGE between January 2024 and March 2025. Eligible patients were categorized into an exposed group receiving Erxiekang Emplastra plus standard therapy and an unexposed group receiving standard therapy alone. The primary outcome was diarrhea duration; secondary outcomes included the 3-day Modified Vesikari Scale (MVS) and treatment-related adverse events. Multivariable linear regression was conducted to quantify the independent therapeutic benefits of the Erxiekang Emplastra.

RESULTS

A total of 1,089 eligible patients were included, with 417 in the exposed group and 672 in the unexposed group. The exposed group had significantly shorter diarrhea duration (3.83 vs. 4.92 days, p < 0.01) and lower 3-day MVS (2.90 vs. 4.51, p < 0.01). Adjunctive Erxiekang Emplastra was independently associated with reduced diarrhea duration (β = -0.38, p < 0.01; R2 = 0.19) and lower 3-day MVS (β = -0.44, p < 0.01; R2 = 0.22). Only 1.44% of patients developed mild transient local reactions, with no severe adverse events reported.

CONCLUSION

Erxiekang Emplastra showed favorable tolerability in this pediatric AGE cohort, and its adjunctive use was independently associated with shortened diarrhea duration and reduced disease severity. Large-scale, multicenter, prospective randomized controlled trials are warranted to confirm the efficacy and safety of this intervention.

Для цитирования: Fang Cuiyun, Zhou Yuan, Jiang Zhongli, Su Xiaoxue, Fan Wei. Erxiekang emplastra as adjunctive therapy for acute gastroenteritis in children: a single-center retrospective cohort study.. Frontiers in pediatrics. 2026. DOI: 10.3389/fped.2026.1832504.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.